Showing results (1451-1460 of 1,513) with videos related to
Sort By:
Pageof 152
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trialDong-Wan Kim, Dae Ho Lee, Ji-Youn Han, et al.Journal of Neuro-Oncology|November 6, 2010
Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trialIl Han Kim, Chul-Kee Park, Dae Seog Heo, et al.The New England Journal of Medicine|June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancerAlice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.Journal of Gastroenterology and Hepatology|April 5, 2016
Asian consensus statements on endoscopic management of walled-off necrosis Part 1: Epidemiology, diagnosis, and treatmentHiroyuki Isayama, Yousuke Nakai, Rungsun Rerknimitr, et al.Investigational New Drugs|August 8, 2017
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testingKyoungmin Lee, Changhoon Yoo, Kyu-Pyo Kim, et al.The Lancet. Oncology|April 17, 2016
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Eng-Huat Tan, Ken O'Byrne, et al.Nature Medicine|February 4, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trialBenjamin Besse, Jessica J Lin, Lyudmila Bazhenova, et al.Therapeutic Advances in Respiratory Disease|November 15, 2019
Noninvasive ventilation failure in patients with hypoxemic respiratory failure: the role of sepsis and septic shockJun Duan, Lijuan Chen, Guopeng Liang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2016
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung CancerShirish M Gadgeel, Alice T Shaw, Ramaswamy Govindan, et al.Clinical Lung Cancer|August 29, 2022
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L StudyMyung J Ahn, Hye R Kim, James C H Yang, et al.Pageof 152